Schrödinger shares are surging today, driven by a combination of company-specific developments and a broader rotation within the software sector. Following the company's presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, where management outlined a strategy for growth and a push into cloud-based solutions, investor sentiment was further bolstered by a positive industry outlook projecting the AI drug discovery market to reach 13.8 billion dollars by 2033. This momentum was amplified by a wider market trend where SaaS stocks received a boost as investors pivoted away from hardware-focused AI plays toward software applications, a shift highlighted by the ongoing debate regarding the pacing of frontier-model development.